Blood eosinophils: a biomarker of response to glucocorticoids and clinical outcomes in hospitalized acute exacerbations of COPD

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039548

Enrollment

Unknown

Registered

2020-10-31

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Gold Standard:Clinical outcome

Index test:blood EOS

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >= 40 years; 2. Meet the diagnostic criteria of AECOPD according to the GOLD 2019; 3. Be able to complete the CAT and mMRC questionnaires independently.

Exclusion criteria

Exclusion criteria: 1. Suffering from other active or chronic respiratory diseases (such as asthma, pneumonia, bronchiectasis, severe sequelae of pulmonary tuberculosis, or lung cancer); 2. Using oral or intravenous glucocorticoids within 48 hours prior to admission; 3. Patients with severe intellectual or cognitive impairments; 4. Participation in any interventional clinical trials.

Design outcomes

Primary

Measure	Time frame
Reactivity Indicators to treatment;future total exacerbation and mortality;SPE, SEN, ACC, AUC of ROC, PPV, NPV;	—

Countries

China

Contacts

Public ContactYan Chen

The Second Hospital of Central South University

chenyan99727@163.com+86 13508471738

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026